BCM
ITCI

Bayesian Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Bayesian Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-14,110
Closed -$213K – 730
2016
Q4 		$213K Buy
+14,110
New +$199K 0.05% 506

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Bayesian Capital Management's ITCI Position: Q1 2017 in Review

Bayesian Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2017, closing a stake of 14,110 shares — an estimated $213K sold.

Bayesian Capital Management first reported a position in ITCI in Q4 2016 and held it in 1 quarter. The position peaked at $213K in Q4 2016. 117 funds tracked by Wall St. Rank hold ITCI as of Q1 2017.

  • Bayesian Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2017 after selling out during the quarter.
  • Bayesian Capital Management sold 14,110 Intra-Cellular Therapies Inc. shares in Q1 2017, an estimated $213K.
  • Bayesian Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 1 quarter.
  • Bayesian Capital Management's Intra-Cellular Therapies Inc. position peaked at $213K in Q4 2016.
  • 117 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2017.

Based on Bayesian Capital Management's 13F filing for Q1 2017, filed 15 May 2017.